The company will begin offering Thermo Fisher's Oncomine Focus Assay and the Oncomine Comprehensive Assay.
Electrochemical clamp assays, developed at the university could expand Xagenic's X1 platform into the liquid biopsy space.
In the study, called TAPUR, ASCO will give cancer patients who are out of treatment options off-label drugs based on their genomic data and record their outcomes in a registry.
The partners are collaborating to provide US-based cancer patients with access to therapeutic clinical trials and molecular diagnostic decision support.
Nemucore will use MPI's technology to potentially identify patients who will respond to an investigational cancer treatment.
In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.
The New York Times editorial board weighs in on scientific research misconduct.
The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.
The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.